Association between fibrinogen and fibrinogen γ’ and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study

Citation for published version (APA):

Document status and date:
Published: 01/05/2019

DOI:
10.1016/j.thromres.2019.02.030

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 03 Nov. 2023
Full Length Article

Association between fibrinogen and fibrinogen γ' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study

A.C. van Dijka,b,1, S.J. Donkela,c,1, T. Zadia, M.A.H. Sonneveldc, F.H.B.M. Schreuderd,e, M.F. Chohanc, P.J. Koudstaalb, F.W.G. Leebeekc, R. Saxena1, J. Hendrikseg, M.E. Koohi,h,i, A. van der Lugta, M.P.M. de Maatc,⁎

a Department of Radiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands
b Department of Neurology, Erasmus MC, University Medical Center Rotterdam, the Netherlands
c Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands
d Department of Clinical Neurophysiology, Maastricht University Medical Center, Maastricht, the Netherlands
e Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
f Department of Neurology, Maasstad hospital, Rotterdam, the Netherlands
g Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands
h Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
i Department of CARDIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands

ARTICLE INFO

Keywords: von Willebrand factor Fibrinogen Atherosclerosis Stroke Magnetic resonance imaging Computed tomography angiography

ABSTRACT

Introduction: Von Willebrand Factor (VWF), ADAMTS13, fibrinogen and fibrinogen γ' are associated with an increased risk of ischemic stroke. Carotid atherosclerosis is an important risk factor for ischemic stroke. Characteristics of the vulnerable plaque; intraplaque hemorrhage (IPH), plaque ulceration and lipid-rich necrotic core (LRNC) can be visualized with imaging techniques. Since atherosclerosis might attribute to the association between coagulation factors and ischemic stroke risk, the aim of this study is to investigate the association between coagulation factors and atherosclerotic plaque characteristics in more detail.

Materials and methods: In 182 patients of the Plaque-At-RISK study (prospective multicenter cohort study) with a recent transient ischemic attack (TIA) or ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis, we measured VWF antigen (VWF:Ag), ADAMTS13 activity, fibrinogen (Clauss), and fibrinogen γ'. Presence of plaque ulceration, IPH volume and LRNC volume were determined by Multidetector-Row Computed Tomography (MDCTA, n = 160) and Magnetic Resonance Imaging (MRI, n = 172). Linear regression analysis was used to assess the association between imaging biomarkers and coagulation factors.

Results: VWF:Ag or ADAMTS13 levels were not significantly associated with plaque ulceration, IPH and LRNC. We found an inverse association between fibrinogen and fibrinogen γ' and IPH volume (B = −23.40 mm^3/g/L, p = 0.01) and between fibrinogen and fibrinogen γ' and LRNC volume (B = −38.89 mm^3/g/L, p < 0.01 and B = −227.06 mm^3/g/L, p = 0.01). Additional adjustments for C-reactive protein (CRP) did not change the results.

Conclusions: Fibrinogen and fibrinogen γ' are inversely associated with IPH volume and LRNC volume, independent of inflammation.

Clinical Trial Registration: clinicaltrials.gov NCT01208025

1. Introduction

Atherosclerosis of the carotid arteries is an important risk factor for the development of ischemic stroke [1]. Presence of plaque ulceration, intraplaque hemorrhage (IPH) and a lipid-rich necrotic core (LRNC) are important characteristics of the vulnerable plaque, a plaque more prone...
to rupture and causing an ischemic event [2]. Presence of IPH has been associated with a ~6-fold higher risk for ischemic events (stroke, transient ischemic attack or amaurosis fugax) [3]. IPH and LRNC can be assessed and quantified by Magnetic Resonance Imaging (MRI). Rupture of the atherosclerotic plaque can be visible as plaque ulceration on Multidetector-row Computed Tomography (MDCTA) [4]. Rupture of the plaque leads to activation of primary and secondary hemostasis and formation of a thrombus which can eventually lead to occlusion of an artery of the brain and ischemic stroke or transient ischemic attack (TIA).

VWF has an important function in primary hemostasis via its role in platelet adhesion and aggregation. Endothelial damage, for instance in plaque ulceration, leads to increased plasma levels of VWF. A Disintegrin And Metalloprotease with Thrombospondin motif repeats 13 (ADAMTS13) cleaves large VWF multimers into smaller and less prothrombotic forms [5]. High VWF and low ADAMTS13 levels are associated with an increased risk of ischemic stroke and myocardial infarction [6,7]. One candidate mechanism underlying the association between VWF and ischemic stroke may be atherosclerosis. Previous studies suggest that atherosclerosis is a determinant of VWF levels [8]. In vitro and in vivo studies also suggest that VWF might contribute to the pathogenesis of atherosclerosis, where VWF deficiency showed to be protective against atherosclerosis [9–11]. When taking all these studies together, the data on the relation between VWF and atherosclerosis are inconclusive.

Fibrinogen is a key element of secondary hemostasis and also acts as an acute phase reactant in inflammation. Several isoforms of fibrinogen are present in the blood; circulating fibrinogen consists for 8–15% of an acute phase reactant in inflammation. Several isoforms of fibrinogen on the relation between VWF and atherosclerosis are inconclusive. 2.2. Cardiovascular risk factors

Clinical baseline data such as age, sex, body mass index, type of stroke, medication use, medical history and cardiovascular risk factors were collected. Hypercholesterolemia was defined as fasting total cholesterol of > 5 mmol/L or the use of cholesterol-lowering medication at the time of the TIA or ischemic stroke. We defined hypertension as systolic blood pressure of > 140 mmHg or a diastolic blood pressure of > 90 mmHg during 2 episodes of at least 15 min of continuous noninvasive blood pressure measurement or treatment with anti-hypertensive medication. Diabetes mellitus was defined as a fasting serum glucose level of > 6.9 mmol/L, 2-hour postload glucose level of > 11.0 mmol/L, or the use of antidiabetic medication. We assessed smoking status at the time of the TIA or ischemic stroke and dichotomized it into current smoker or non current smoker. History of CVD was defined as history of TIA or ischemic stroke, history of ischemic heart disease and/or history of peripheral artery disease.

2.3. MDCTA and 3 T MRI data acquisition and analysis

Standardized, previously described, contrast-enhanced MDCTA and multi-sequence contrast-enhanced MRI protocols were used [17]. All imaging studies were evaluated by trained readers blinded for clinical data and other imaging tests [19]. MDCTA images were reviewed using dedicated 3D analysis software (Syngo.via; Siemens, Erlangen, Germany). First, image quality was rated on a 3-point scale; poor (not eligible for analysis), moderate and good (eligible for analysis) [19]. Secondly, presence of plaque ulceration was assessed. We defined plaque ulceration as an extension of contrast material of > 1 mm into the atherosclerotic plaque on at least 2 orthogonal planes [20,21]. In addition, the most severe stenosis in the symptomatic carotid bifurcation and internal carotid artery was measured according to the ECST criteria, perpendicular to the central lumen line [18]. Finally, a custom-made plug-in for the freely available Image J software (National Institutes of Health, Bethesda, Maryland) was used to quantify calcifications in the symptomatic carotid artery within 3 cm proximal and distal to the bifurcation. We used a threshold of 600 HU to differentiate calcifications from contrast material in the lumen; calcification volume was expressed in cubic millimeters. A detailed description of the measurements is provided elsewhere [22].

MR images were evaluated with dedicated vessel wall analysis software (Vesselpass, Department of Radiology, Leiden University Medical Center, Netherlands). Information of all five MRI carotid artery sequences was used. Image quality was rated on a 5-point scale; poor and not eligible for analysis (1) to good and eligible for analysis (5) [19]. MR images were automatically registered by delineating the lumen and outer vessel wall of the symptomatic carotid artery. Registration was manually corrected if needed. Plaque components of the symptomatic carotid artery (IPH, lipid-rich necrotic core, calcifications) were manually segmented. Fifteen transverse adjoining slices of 2 mm
each covering the entire plaque were annotated. Additionally to plaque component volumes, maximum vessel wall area and other plaque component volumes of the symptomatic carotid artery could be derived from these annotations.

2.4. Blood sampling, VWF levels, ADAMTS13 activity, fibrinogen and fibrinogen γ’ measurements

Citrated blood was centrifuged at 2000g for 10 min; then the plasma was centrifuged at 14,000g for 10 min and stored in aliquots at –80°C. VWF:Antigen (VWF:Ag) levels were measured with an in-house ELISA, using polyclonal rabbit anti-human VWF antibodies (Dakocytomation, Glostrup, Denmark) for catching and tagging. ADAMTS13 activity was measured using the Fluorescence Resonance Energy Transfer Substrate VWF 73 (FRETs-VWF73) [23]. Total fibrinogen levels were measured according to von Clauss on a fully-automated coagulation analyzer (Sysmex CS-5100 system, Siemens Healthcare Diagnostics, Breda, the Netherlands). Fibrinogen γ’ antigen levels were measured with an enzyme-linked immunosorbent assay as described previously using anti-γ’ fibrinogen antibodies for catching and HRP-labeled rabbit anti-fibrinogen antibodies for tagging [24].

2.5. Statistical analysis

Baseline clinical characteristics and blood measurements are listed for all patients. All available imaging characteristics, including plaque ulceration and IPH, are shown for the symptomatic carotid artery. Data are presented as mean ± standard deviation (SD), median [25th–75th percentile] or number of patients (%). Differences between the two groups were evaluated by using the student percentile or number of patients (%). Differences between the two are presented as mean ± standard deviation (SD), median [25th–75th].

### Table 1

<table>
<thead>
<tr>
<th>Clinical characteristic (n=182)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Classification event</td>
</tr>
<tr>
<td>TIA</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
<tr>
<td>Amaurosis fugax</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>Current smoking</td>
</tr>
<tr>
<td>BMI</td>
</tr>
<tr>
<td>History of CVD</td>
</tr>
<tr>
<td>Blood group non-O</td>
</tr>
<tr>
<td>Medication use prior to event</td>
</tr>
<tr>
<td>Statins</td>
</tr>
<tr>
<td>Antiplatelet drugs</td>
</tr>
<tr>
<td>Anticoagulants</td>
</tr>
</tbody>
</table>

## 3. Results

Baseline clinical characteristics, imaging characteristics and blood measurements are shown in Table 1. In our patients, the mean age was 67 ± 9 years and 74% were male. Hypercholesterolemia was present in 78% of the patients and hypertension was present in 71% of the patients. A history of CVD before the index event was highly prevalent amongst patients (49%). Prevalence of plaque ulceration on MDCTA was 28%. Prevalence of IPH in the symptomatic plaque on MRI was 39%. Blood measurements showed a median VWF:Ag level of 1.45 [1.10–1.81] IU/mL, ADAMTS13 activity of 98.6 ± 22.8%, mean fibrinogen of 3.68 ± 0.72 g/L, and a mean fibrinogen γ’ of 0.36 ± 0.14 g/L.

### 3.1. Primary hemostasis: VWF:Ag levels and ADAMTS13 activity

Focusing on factors of primary hemostasis, we found that increasing age was associated with higher VWF:Ag levels (B = 0.12 IU/mL/10 years [95% CI 0.03–0.21], p = 0.01). Individuals with blood group non-O had higher VWF:Ag levels compared with individuals with blood group O (B = 0.22 IU/mL [95% CI 0.10–0.33], p < 0.001). Age was inversely associated with ADAMTS13 activity (B = −6.22%/10 years
Association between VWF:Ag levels, ADAMTS13 activity, fibrinogen or fibrinogen γ' and plaque ulceration, intraplaque hemorrhage and lipid-rich necrotic core.

### Table 2

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Primary hemostasis</th>
<th>Secondary hemostasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VWF:Aga (IU/mL)</td>
<td>ADAMTS13 (%)</td>
</tr>
<tr>
<td></td>
<td>B [95% CI]</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plaque ulceration</td>
<td>–0.08 [–0.23;0.06]</td>
<td>0.25</td>
</tr>
<tr>
<td>IPH volume (mm³)</td>
<td>−17.13 [–52.22;17.95]</td>
<td>0.34</td>
</tr>
<tr>
<td>Adjustment for CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LRNC volume (mm³)</td>
<td>−18.38 [–66.94;30.18]</td>
<td>0.46</td>
</tr>
<tr>
<td>Adjustment for CRP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Adjusted for age and sex, smoking, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, history of cardiovascular disease and peripheral arterial disease; additionally for blood group non-O in case of VWF.

### Discussion

This study shows a significant inverse association between biomarkers of secondary hemostasis; fibrinogen and fibrinogen γ' and IPH volume and LRNC volume, in patients with a recent TIA or ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis. No
associations were found between markers of primary hemostasis, VWF:Ag levels or ADAMTS13 activity and plaque ulceration, IPH volume and LRNC volume. To the best of our knowledge, this study is the first to investigate the relationship between the specific vulnerable plaque characteristics plaque ulceration and intraplaque hemorrhage with markers of primary and secondary hemostasis.

4.1. Primary hemostasis; VWF:Ag levels and ADAMTS13 activity

In the current study, no associations were found between VWF and ADAMTS13 and plaque ulceration, IPH, LRNC or additional plaque characteristics. In a previous study, we found a strong correlation between calcification volume in the aortic arch and carotid arteries and VWF levels in patients with an ischemic stroke or TIA. In accordance to literature, in this previous study we also found significantly higher VWF levels in patients with large artery atherosclerosis compared to other etiological subtypes of TIA or stroke [25,26]. It might be that VWF levels are differently associated with plaque burden measurements than with vulnerable plaque characteristics like plaque ulceration, IPH and LRNC. For example, in acute coronary syndrome patients, the presence of atherosclerosis measured by intravascular ultrasound (IVUS) was associated with VWF:Ag levels, but high risk, prone-to-rupture atherosclerotic lesions were not associated with VWF:Ag levels [27]. However, due to the known role of VWF in thrombus formation and the less clear role of VWF and ADAMTS13 in atherosclerotic plaque development, we expected to find the opposite. It seems that neither the local disturbance of blood flow nor the disruptive plaque surface in the carotid bifurcation causes an increase in VWF or a decrease in ADAMTS13. It might be that damage of the endothelial layer due to widespread atherosclerotic disease, causes a change in VWF levels. On these terms, blood coagulation markers are markers of a widespread atherosclerotic disease and not a risk marker for secondary prevention.

However, a complex role of VWF and ADAMTS13 in atherosclerotic plaque development cannot be ruled out.

4.2. Secondary hemostasis; fibrinogen and fibrinogen γ'

Our current finding of an inverse association between fibrinogen and fibrinogen γ’ and IPH volume and LRNC volume suggests a protective role of fibrinogen and fibrinogen γ’ in the development of a vulnerable plaque. This association was independent of CRP and in case of fibrinogen also independent of degree of stenosis. Higher levels of plasma fibrinogen can induce clot formation more easily, possibly resulting in confinement of IPH and a smaller IPH volume and thereby a smaller LRNC volume. The presence of IPH has been shown to enlarge the LRNC [28]. In this study IPH was assessed as part of the LRNC, therefore LRNC and IPH volume were highly correlated.

Some studies on the incidence of CVD and fibrinogen γ’ levels did not find significant associations [15,16]. It might be that fibrinogen γ’ independently does not predict the occurrence of CVD, but that low levels might play a role in the progression of an atherosclerotic plaque due to a larger IPH or LRNC volume.

IPH is assumed to be the result of blood leakage within the core due to leakage of immature intraplaque neovessels [29,30]. These neovessels are formed due to hypoxia inside the atherosclerotic plaque [31]. Another described pathophysiological mechanism of IPH is repeated plaque fissuring followed by the formation of a non-occlusive luminal thrombus that gets incorporated into the atherosclerotic plaque [32]. Membranes of red blood cells contain a high load of unesterified cholesterol, leading to enlargement of the LRNC, and eventually a reduced plaque stability. IPH was observed to increase the risk of subsequent ischemic cerebralvascular events by five times [33].

In this study we found no association between fibrinogen levels and IPH volume or LRNC volume in patients with or without a history of CVD. When adding an interaction term of fibrinogen or fibrinogen γ with a history CVD to the regression model, we found that these variables were not significantly interacting. IPH increases the risk of an ischemic event but not all IPH leads directly to a plaque rupture. IPH can occur at all time points during the progression of an atherosclerotic plaque, also in patients with a history of CVD. As was found in a study of Spagnoli et al. where fresh IPH was observed in carotid plaques from carotid endarterectomy samples of patients up to 24 months after an ischemic stroke [34].

Medication use in patients with and without a history of CVD, including the use of statins and anti-platelet drugs, are important possible confounders to consider. For instance, previous studies show that statins are associated with an increased stabilization of the atherosclerotic plaque, as shown by increased plaque echogenicity [35]. Furthermore, statins have shown to influence levels of several coagulation factors in plasma, including fibrinogen, thereby inducing an anticoagulant effect [36]. A recent study in 1740 participants of a population-based cohort study with carotid atherosclerosis found a positive trend with current or past use of anti-platelet agents and higher presence of IPH [37]. In the present study we found no association between fibrinogen and fibrinogen γ’ with IPH volume and LRNC volume in subgroup analysis of patients with or without a statin or anti-platelet drugs. We also found that there was no interaction between both drugs and these coagulation factors. It might be that both statins and anti-platelet agents are associated with the presence of IPH and a LRNC rather than IPH volume and LRNC volume.

Previous studies on inflammatory biomarkers in atherosclerotic disease highlight a role of CRP and fibrinogen in patients with early stages of atherosclerosis and progression of the atherosclerotic plaque [38]. The CRP levels in our study were relatively low and were no longer affected by acute inflammation during the index event (median interval between event and blood withdrawal was 47 days). In contrast to our results, Buljubasic et al. found a significant association between high fibrinogen levels and coronary plaque burden, but not with plaque composition in patients with acute coronary syndrome or stable angina pectoris as measured by IVUS [39]. However, blood samples were collected before the procedure at a moment of acute inflammation. Fibrinogen is known to be elevated during a state of inflammation; after adjustment for CRP, significance was no longer reached. In addition, IVUS is unable to measure IPH volume, whereas MRI is a sensitive and specific imaging modality suitable for detecting IPH [40]. Sabeti et al. also found an association between high fibrinogen levels at baseline and progression of the atherosclerotic plaque during follow-up, as measured with carotid ultrasound. They found a hazard ratio for progression of atherosclerosis of 2.45 (p = 0.002) between the highest and lowest quartile of baseline fibrinogen [41]. However, also in their study there was no longer a significant association after adjusting for CRP.

A limitation of our study was the cross-sectional design, which precludes the unraveling of cause and effect. We had a median delay of 47 days between index event and blood sampling/imaging, which might have influenced the association via a change in plaque composition and levels of coagulation factors [42]. VWF and fibrinogen are known to be increased in the acute phase of an event [13,43]. However, imaging and blood sampling were performed at the same moment and we found no change in results after additional adjustment for the interval event-blood withdrawal. Moreover, due to the lack of acute phase, levels of blood biomarkers may resemble the levels before the index event.

5. Summary

Fibrinogen and fibrinogen γ’ were inversely associated with IPH volume and LRNC volume in patients with a recent TIA or ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis. No association was found between VWF:Ag levels and ADAMTS13 activity and vulnerable plaque characteristics. The inverse association between fibrinogen and fibrinogen γ’ and IPH volume and LRNC volume appears to be independent of inflammation and suggests a protective role of
fibrinogen and fibrinogen γ' in relation to vulnerable plaque characteristics.

Conflict of interest

FL reports unrestricted research grants from CSL Behring and Shire and is a consultant to UniQure, Shire and NovoNordisk.

Sources of funding

This research was performed within the framework of the Centre for Translational Molecular Medicine (www.ctmm.nl), project PARISK (Plaque At RISK; grant 01C-202) and supported by the Dutch Heart Foundation. This project has received funding from the European Union’s Horizon 2020 - Research and Innovation Framework Programme under the Marie Skłodowska-Curie grant agreement No 722609.

References


